Empire Financial Management Company LLC Increases Holdings in TriSalus Life Sciences, Inc. $TLSI

Empire Financial Management Company LLC increased its position in TriSalus Life Sciences, Inc. (NASDAQ:TLSI) by 316.9% during the first quarter, HoldingsChannel.com reports. The fund owned 300,275 shares of the company’s stock after acquiring an additional 228,248 shares during the quarter. Empire Financial Management Company LLC’s holdings in TriSalus Life Sciences were worth $1,201,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. First Light Asset Management LLC acquired a new position in TriSalus Life Sciences during the first quarter worth $20,267,000. Nantahala Capital Management LLC grew its holdings in TriSalus Life Sciences by 1.5% in the fourth quarter. Nantahala Capital Management LLC now owns 2,070,827 shares of the company’s stock valued at $14,454,000 after purchasing an additional 30,582 shares during the last quarter. Wasatch Advisors LP acquired a new stake in TriSalus Life Sciences in the first quarter valued at $5,752,000. Vanguard Group Inc. grew its holdings in TriSalus Life Sciences by 42.4% in the third quarter. Vanguard Group Inc. now owns 1,159,575 shares of the company’s stock valued at $5,392,000 after purchasing an additional 345,186 shares during the last quarter. Finally, Gilder Gagnon Howe & Co. LLC increased its position in shares of TriSalus Life Sciences by 32.1% in the second quarter. Gilder Gagnon Howe & Co. LLC now owns 1,092,975 shares of the company’s stock valued at $5,957,000 after buying an additional 265,618 shares in the last quarter. 2.58% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, CEO Mary T. Szela acquired 39,682 shares of the firm’s stock in a transaction that occurred on Friday, May 15th. The shares were acquired at an average price of $2.59 per share, with a total value of $102,776.38. Following the completion of the purchase, the chief executive officer directly owned 1,065,215 shares in the company, valued at approximately $2,758,906.85. The trade was a 3.87% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Mats Wahlstrom acquired 60,000 shares of the company’s stock in a transaction that occurred on Friday, May 15th. The shares were bought at an average price of $2.53 per share, with a total value of $151,800.00. Following the transaction, the director owned 147,555 shares in the company, valued at $373,314.15. This represents a 68.53% increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last 90 days, insiders purchased 719,682 shares of company stock valued at $1,804,176. Corporate insiders own 16.30% of the company’s stock.

Analyst Upgrades and Downgrades

TLSI has been the subject of several research reports. Weiss Ratings downgraded TriSalus Life Sciences from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, May 13th. Lake Street Capital lowered their price objective on shares of TriSalus Life Sciences from $10.00 to $8.00 and set a “buy” rating on the stock in a research note on Wednesday, May 13th. Two analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $7.50.

TriSalus Life Sciences Trading Up 0.2%

Shares of TriSalus Life Sciences stock opened at $4.33 on Wednesday. TriSalus Life Sciences, Inc. has a 1 year low of $2.20 and a 1 year high of $7.95. The company has a debt-to-equity ratio of 2.58, a current ratio of 5.78 and a quick ratio of 5.46. The business has a 50 day moving average price of $3.93 and a 200 day moving average price of $4.36. The company has a market capitalization of $265.95 million, a P/E ratio of -3.07 and a beta of 0.43.

TriSalus Life Sciences Profile

TriSalus Life Sciences, Inc is a clinical-stage biotechnology company focused on the development and commercialization of non-invasive drug–device combination therapies for oncology applications. Leveraging proprietary electroporation and ultrasound platforms, the company aims to enhance the localized delivery and efficacy of established chemotherapeutic agents while reducing systemic toxicity. Its lead programs target hard-to-treat head and neck cancers, where improved tumor control and patient tolerability remain significant unmet needs.

The company’s pipeline comprises investigational product candidates in early and mid-stage clinical trials, including studies that combine its electrochemotherapy platform with radiation therapy and immuno-oncology agents.